GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Quick Ratio
中文

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Quick Ratio : 9.52 (As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

EOM Pharmaceutical Holdings Quick Ratio Definition

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. EOM Pharmaceutical Holdings's quick ratio for the quarter that ended in Jun. 2018 was 9.52.

EOM Pharmaceutical Holdings has a quick ratio of 9.52. It generally indicates good short-term financial strength.

The historical rank and industry rank for EOM Pharmaceutical Holdings's Quick Ratio or its related term are showing as below:

IMUC's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.56
* Ranked among companies with meaningful Quick Ratio only.

EOM Pharmaceutical Holdings Quick Ratio Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.26 18.96 10.31 3.78 2.97

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.92 2.97 3.46 9.52

Competitive Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Quick Ratio falls into.



EOM Pharmaceutical Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

EOM Pharmaceutical Holdings's Quick Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Quick Ratio (A: Dec. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(7.009-0)/2.361
=2.97

EOM Pharmaceutical Holdings's Quick Ratio for the quarter that ended in Jun. 2018 is calculated as

Quick Ratio (Q: Jun. 2018 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(3.829-0)/0.402
=9.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


EOM Pharmaceutical Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077